eligibility_summary
Eligible: Multiple myeloma, 1–3 prior lines including ≥2 consecutive cycles of an IMiD and an anti‑CD38 mAb, IMWG-defined progression within 12 months, measurable disease, ECOG 0–1, eligible for PVd/DPd/KDd/Kd, females of childbearing potential need a negative pregnancy test. Exclude: prior BCMA, T‑cell engager, or CAR‑T, CNS/cardiac MM, PCL, WM, POEMS, amyloidosis, other active cancer or MDS, recent auto (<12 wks)/allo‑SCT, recent high‑dose steroids/immunosuppression, live vaccine ≤4 wks, F/C contraindication, severe DMSO allergy, life expectancy <12 wks.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 3 RCT in relapsed/refractory multiple myeloma comparing anitocabtagene autoleucel (CART‑ddBCMA) vs standard regimens (PVd, DPd, KDd, Kd). Anitocabtagene autoleucel: autologous CAR‑T cell therapy using a D‑domain CAR binder to BCMA (TNFRSF17), after lymphodepletion (cyclophosphamide—alkylating DNA crosslinker, fludarabine—purine analog), infused CAR‑T cells recognize BCMA on malignant plasma cells and induce T‑cell activation and cytotoxic killing. SOCT mechanisms: pomalidomide (oral IMiD, CRBN E3 ligase modulator causing IKZF1/3 degradation, boosts T/NK activity), bortezomib (reversible 26S proteasome inhibitor), carfilzomib (irreversible proteasome inhibitor), daratumumab (anti‑CD38 IgG1 mAb, ADCC/CDC/ADCP), dexamethasone (glucocorticoid). Cells/pathways targeted: BCMA+ plasma cells, CD38+ myeloma cells, proteasome, CRBN‑IKZF axis, glucocorticoid receptor, lymphodepletion to aid CAR‑T expansion.